FOLD earnings call for the period ending September 30, 2019.
News & Analysis: Amicus Therapeutics
The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.
The competitive outlook for a key therapy is worrying investors.
Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.
FOLD earnings call for the period ending June 30, 2019.
Amicus' shares shot up by 10.7% last month. Here's why.
Earnings and other concerns held some stocks back Thursday.
The company announced a significant stock offering.
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.
FOLD earnings call for the period ending March 31, 2019.